Developer docs
API playgroundTry for free, no card

Search company profiles

Elucidata

Full company profile

uuid0000b9z

Namestring
Elucidata
Legal namestring
Elucidata Corporation
Websiteurl
elucidata.io
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Elucidata is a biomedical data platform company founded in 2015 that delivers ML-ready, curated molecular data to accelerate drug discovery. Its flagship platform, Polly, is a multi-modal agentic stack for target validation that ingests proprietary and public biomedical data, connects evidence through knowledge graphs, scores candidate targets across 14 dimensions, and delivers ranked, decision-ready target shortlists. The platform is modular — comprising Polly Scout (AI-powered public dataset discovery), Atlas (multi-modal data harmonization), Polly Xtract (NLP document processing), Co-Scientist (agentic discovery workflows), Polly Knowledge Graph, Data Concierge, and PollyGPT — and supports cloud, on-premise, or hybrid deployment. A multi-agent AI system for metadata curation achieves 93% recall across 23 metadata fields and outperforms GPT-4.1 on accuracy, F1, and traceability; Elucidata also enables foundation-model fine-tuning such as scGPT for cell-type annotation and batch-effect correction.

The company serves enterprise pharmaceutical companies (Eli Lilly, Bristol Myers Squibb, Pfizer, Janssen, Boehringer Ingelheim, Otsuka, Chugai), biotech firms (Alnylam, Owkin, Atavistik, CTRL Therapeutics, Immutas, Auron, Immunitas, Exelixis), research institutions (Stanford, DeepMind), and emerging biotech, with 90+ biopharma partners and 40+ programs advanced beyond IND. Elucidata earns revenue through annual SaaS subscriptions to Polly, professional services billed as Statements of Work for implementation and custom bioinformatics pipelines, and recurring managed services such as Data Concierge and Metadata Curation. The company runs an enterprise field-sales motion targeting R&D IT leaders and translational scientists at top pharma and biotech firms, with offices in San Francisco (operational HQ), Cambridge (legal HQ), Boston, New Delhi, and Bengaluru. Notable recent moves include the January 2026 launch of AI Labs for biomedical AGI research and a May 2025 biobank partnership with Sapien Biosciences.

Short descriptiontext

Elucidata provides Polly, an AI-native biomedical data platform that harmonizes multi-modal omics and clinical data into knowledge graphs to help pharmaceutical and biotech companies identify and validate drug targets, serving 90+ biopharma R&D partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biomedical data curation, drug discovery software, multi-omics analysis, target validation platform, knowledge graph software
Industry4 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAN
Knowledge Management & Scientific Collaboration / Literature Intelligence
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Software Publishers5132
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Drug Discovery & Biomedical Data Analytics Software
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Subscription Services (SaaS)
TypeSubscription Recurring
Description

Software subscription services for access to Polly platform. Customers pay subscription fees for platform access during the subscription term. Professional services available for implementation and custom development.

elucidata.io
2Professional Services
TypeProfessional Services
Description

Software implementation and development services including custom bioinformatics pipelines, data integration, and platform customization. Billed as Statements of Work alongside subscription services.

elucidata.io
3Managed Services
TypeManaged Services
Description

Ongoing managed data services including Data Concierge, Metadata Curation, and Data Quality Assessments delivered as recurring services.

elucidata.io
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Enterprise subscription with customizable modules and professional services
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based pricing tailored to customer requirements, number of users, and scope of platform access. Annual subscription terms standard.

elucidata.io
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Polly
Description

Multi-Modal Agentic Stack for Target Validation - AI-powered platform for biomedical data harmonization, knowledge graphs, and drug discovery target identification.

elucidata.io
Core offering1 text field

Elucidata delivers ML-ready, curated biomedical molecular data and operates Polly, a multi-modal agentic stack for target validation in drug discovery. Polly ingests proprietary and public biomedical data, connects evidence through knowledge graphs, scores target candidates across 14 dimensions, and delivers ranked decision-ready target lists. The platform is supplemented by managed services (Data Concierge, Metadata Curation, Data Quality Assessments, custom bioinformatics pipelines) and supports cloud, on-premise, or hybrid deployment for biopharma R&D teams.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 40% reduction in data preparation time for biopharma company
+7 more records
Product overview1 text field

Elucidata offers Polly, a Multi-Modal Agentic Stack for Target Validation, designed as a unified platform with modular components for drug discovery. The core Polly platform is supplemented by specialized modules including Polly Scout (public dataset discovery), Polly Atlas (data harmonization), Polly Knowledge Graph (evidence connections), Polly Xtract (document processing), Co-Scientist (agentic workflows), and Data Concierge (data curation). Additional offerings include PollyGPT for natural language querying, Metadata Curation, Data Quality Assessments, Bioinformatics Pipelines, and Custom Apps & Dashboards. The platform supports deployment across cloud, on-premise, or hybrid environments with Security & Compliance controls for regulated R&D. Recent additions include AI Labs for biomedical AGI research and Biologics Data Management for protein-based therapy pipelines.

Product and service3 records
1Polly
CategoryDrug Discovery Software Platform
Description

Multi-Modal Agentic Stack for Target Validation that ingests proprietary and public biomedical data, connects it through a knowledge graph, scores candidates across 14 dimensions, and delivers ranked decision-ready target lists. Sold as a SaaS subscription to biopharma R&D teams with cloud, on-premise, or hybrid deployment options.

2AI Labs
CategoryAI Research Initiative
Description

Initiative for developing advanced AI solutions for biomedical AGI, focusing on out-of-distribution detection and analysis across human, plant, and animal health applications.

3Biologics Data Management (BDM)
CategoryBiologics R&D Software
Description

Scalable biologics inventory data management via hosted platform for managing sequences, physical properties, cell lines, and production runs for protein-based, RNA, lipid, and small molecule therapeutics.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-18
Description

Cross-industry panel participation at IDBS i3 2026 forum in Boston. Elucidata joined IDBS, AWS, and Boehringer Ingelheim to reinforce that reliable AI execution depends on structured, contextualized data foundations and governance.

2AWS
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-18
Description

Cross-industry panel participation at IDBS i3 2026 forum. AWS and Elucidata both contributed to discussions on reliable AI execution and structured data foundations for BioPharma.

prnewswire.com
3Boehringer Ingelheim
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-18
Description

Cross-industry panel participation at IDBS i3 2026 forum showcasing real-world outcomes from data-driven BioPharma implementations with measurable operational gains.

prnewswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-29
Description

Strategic partnership announced to transform biobank assets into high-quality AI products. Collaboration focuses on converting biobank samples and data into structured, analysis-ready datasets for AI-driven drug discovery.

Strategic tierCoreTypeTechnology or Integration
Description

Integration partnership for customizing Genedata Biologics for internal processes and instruments. Delivers purpose-built integrations and last-mile customizations eliminating manual data transfer errors.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Tempus
TypeBroad incumbent
Description

Tempus builds large-scale multimodal biomedical data libraries and AI models, selling data and tools to biopharma in a category that overlaps Elucidata's multi-omics + clinical data positioning.

TypeDirect peer
Description

Datavant connects and de-identifies health data for research, comparable to Elucidata's multi-modal data harmonization and EHR integration work for biopharma customers.

TypeDirect peer
Description

Schrödinger provides computational chemistry and biology software used by pharma for molecular design and target evaluation, overlapping directly with Elucidata's drug discovery software customer base.

TypeDirect peer
Description

Insitro combines ML with biological data for target discovery and drug development, targeting similar biopharma customers and competing for the same platform-of-record position in AI-driven R&D.

TypeBroad incumbent
Description

IQVIA is a large life sciences technology and data provider offering R&D informatics, real-world data, and AI tools to pharma — competing with Elucidata for the same enterprise research IT budgets.

TypeDirect peer
Description

Owkin applies AI to biomedical and clinical data for drug discovery and target identification, selling into the same biopharma R&D buyer base as Elucidata and using multi-modal data and federated learning approaches.

TypeBroad incumbent
Description

Benchling is a widely deployed cloud platform for R&D data, especially in biologics, and competes with Elucidata as the system-of-record for biopharma experimental and molecule data.

TypeDirect peer
Description

DNAnexus provides a cloud platform for biomedical data management and analysis, including multi-omics, similar to Elucidata's Polly Atlas and harmonization infrastructure for biopharma R&D.

TypeBroad incumbent
Description

Recursion combines high-content biology data with ML for drug discovery at much larger scale and capital intensity, competing for the same enterprise pharma partnerships and AI-drug-discovery narrative.

TypeBroad incumbent
Description

Genedata provides enterprise R&D informatics platforms including Genedata Biologics, used by top biopharma for biologics data management — directly overlapping Elucidata's Biologics Data Management offering.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers20 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI capability10 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature11 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Elucidata

Drug Discovery & Biomedical Data Analytics Softwareelucidata.io

Elucidata provides Polly, an AI-native biomedical data platform that harmonizes multi-modal omics and clinical data into knowledge graphs to help pharmaceutical and biotech companies identify and validate drug targets, serving 90+ biopharma R&D partners.

What Elucidata does

Elucidata is a biomedical data platform company founded in 2015 that delivers ML-ready, curated molecular data to accelerate drug discovery. Its flagship platform, Polly, is a multi-modal agentic stack for target validation that ingests proprietary and public biomedical data, connects evidence through knowledge graphs, scores candidate targets across 14 dimensions, and delivers ranked, decision-ready target shortlists. The platform is modular — comprising Polly Scout (AI-powered public dataset discovery), Atlas (multi-modal data harmonization), Polly Xtract (NLP document processing), Co-Scientist (agentic discovery workflows), Polly Knowledge Graph, Data Concierge, and PollyGPT — and supports cloud, on-premise, or hybrid deployment. A multi-agent AI system for metadata curation achieves 93% recall across 23 metadata fields and outperforms GPT-4.1 on accuracy, F1, and traceability; Elucidata also enables foundation-model fine-tuning such as scGPT for cell-type annotation and batch-effect correction.

The company serves enterprise pharmaceutical companies (Eli Lilly, Bristol Myers Squibb, Pfizer, Janssen, Boehringer Ingelheim, Otsuka, Chugai), biotech firms (Alnylam, Owkin, Atavistik, CTRL Therapeutics, Immutas, Auron, Immunitas, Exelixis), research institutions (Stanford, DeepMind), and emerging biotech, with 90+ biopharma partners and 40+ programs advanced beyond IND. Elucidata earns revenue through annual SaaS subscriptions to Polly, professional services billed as Statements of Work for implementation and custom bioinformatics pipelines, and recurring managed services such as Data Concierge and Metadata Curation. The company runs an enterprise field-sales motion targeting R&D IT leaders and translational scientists at top pharma and biotech firms, with offices in San Francisco (operational HQ), Cambridge (legal HQ), Boston, New Delhi, and Bengaluru. Notable recent moves include the January 2026 launch of AI Labs for biomedical AGI research and a May 2025 biobank partnership with Sapien Biosciences.

Elucidata firmographics

Firmographics
Name
Elucidata
Legal name
Elucidata Corporation
Website
https://elucidata.io
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Short description
Elucidata provides Polly, an AI-native biomedical data platform that harmonizes multi-modal omics and clinical data into knowledge graphs to help pharmaceutical and biotech companies identify and validate drug targets, serving 90+ biopharma R&D partners.
Ownership category
akta.pro rank

Elucidata industry classification

Industry
Product category
Drug Discovery & Biomedical Data Analytics Software
NAICS
Software Publishers (5132)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAN
Knowledge Management & Scientific Collaboration / Literature Intelligence
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Biomedical data curation
  • Drug discovery software
  • Multi-omics analysis
  • Target validation platform
  • Knowledge graph software

Where Elucidata is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Elucidata business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Subscription Services (SaaS): Software subscription services for access to Polly platform. Customers pay subscription fees for platform access during the subscription term. Professional services available for implementation and custom development.
  2. Professional Services: Software implementation and development services including custom bioinformatics pipelines, data integration, and platform customization. Billed as Statements of Work alongside subscription services.
  3. Managed Services: Ongoing managed data services including Data Concierge, Metadata Curation, and Data Quality Assessments delivered as recurring services.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise subscription with customizable modules and professional services

Go-to-market motion3 records

Distribution channels4 records

Marketing channels9 records

Elucidata product offering

Product offering

Core offering

Elucidata delivers ML-ready, curated biomedical molecular data and operates Polly, a multi-modal agentic stack for target validation in drug discovery. Polly ingests proprietary and public biomedical data, connects evidence through knowledge graphs, scores target candidates across 14 dimensions, and delivers ranked decision-ready target lists. The platform is supplemented by managed services (Data Concierge, Metadata Curation, Data Quality Assessments, custom bioinformatics pipelines) and supports cloud, on-premise, or hybrid deployment for biopharma R&D teams.

Product overview

Elucidata offers Polly, a Multi-Modal Agentic Stack for Target Validation, designed as a unified platform with modular components for drug discovery. The core Polly platform is supplemented by specialized modules including Polly Scout (public dataset discovery), Polly Atlas (data harmonization), Polly Knowledge Graph (evidence connections), Polly Xtract (document processing), Co-Scientist (agentic workflows), and Data Concierge (data curation). Additional offerings include PollyGPT for natural language querying, Metadata Curation, Data Quality Assessments, Bioinformatics Pipelines, and Custom Apps & Dashboards. The platform supports deployment across cloud, on-premise, or hybrid environments with Security & Compliance controls for regulated R&D. Recent additions include AI Labs for biomedical AGI research and Biologics Data Management for protein-based therapy pipelines.

Differentiator

Problem solved

Functional benefit

Brands

  • Polly: Multi-Modal Agentic Stack for Target Validation - AI-powered platform for biomedical data harmonization, knowledge graphs, and drug discovery target identification.

Products and services

  • Polly Multi-Modal Agentic Stack for Target Validation that ingests proprietary and public biomedical data, connects it through a knowledge graph, scores candidates across 14 dimensions, and delivers ranked decision-ready target lists. Sold as a SaaS subscription to biopharma R&D teams with cloud, on-premise, or hybrid deployment options.
  • AI Labs Initiative for developing advanced AI solutions for biomedical AGI, focusing on out-of-distribution detection and analysis across human, plant, and animal health applications.
  • Biologics Data Management (BDM) Scalable biologics inventory data management via hosted platform for managing sequences, physical properties, cell lines, and production runs for protein-based, RNA, lipid, and small molecule therapeutics.

Quantifiable outcome

  • 40% reduction in data preparation time for biopharma company
  • +7 more outcomes

Companies that use Elucidata

Customer profile

Named customers20 records

Segments5 records

Ideal customer profiles3 records

Elucidata technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability10 records

Feature11 records

Elucidata partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • IDBScoreTechnology or Integration · 18 May 2026Cross-industry panel participation at IDBS i3 2026 forum in Boston. Elucidata joined IDBS, AWS, and Boehringer Ingelheim to reinforce that reliable AI execution depends on structured, contextualized data foundations and governance.
  • AWScoreTechnology or Integration · 18 May 2026Cross-industry panel participation at IDBS i3 2026 forum. AWS and Elucidata both contributed to discussions on reliable AI execution and structured data foundations for BioPharma.
  • Boehringer IngelheimcoreTechnology or Integration · 18 May 2026Cross-industry panel participation at IDBS i3 2026 forum showcasing real-world outcomes from data-driven BioPharma implementations with measurable operational gains.
  • Sapien BiosciencescoreStrategic or Co-development Partner · 29 May 2025Strategic partnership announced to transform biobank assets into high-quality AI products. Collaboration focuses on converting biobank samples and data into structured, analysis-ready datasets for AI-driven drug discovery.
  • Genedata BiologicscoreTechnology or IntegrationIntegration partnership for customizing Genedata Biologics for internal processes and instruments. Delivers purpose-built integrations and last-mile customizations eliminating manual data transfer errors.

Scale indicators14 records

Recent moves6 records

Expansion highlights5 records

Elucidata competitors and assessment

Company assessment

Broad incumbents

  • Tempus: Tempus builds large-scale multimodal biomedical data libraries and AI models, selling data and tools to biopharma in a category that overlaps Elucidata's multi-omics + clinical data positioning.
  • IQVIA: IQVIA is a large life sciences technology and data provider offering R&D informatics, real-world data, and AI tools to pharma — competing with Elucidata for the same enterprise research IT budgets.
  • Benchling: Benchling is a widely deployed cloud platform for R&D data, especially in biologics, and competes with Elucidata as the system-of-record for biopharma experimental and molecule data.
  • Recursion Pharmaceuticals: Recursion combines high-content biology data with ML for drug discovery at much larger scale and capital intensity, competing for the same enterprise pharma partnerships and AI-drug-discovery narrative.
  • Genedata: Genedata provides enterprise R&D informatics platforms including Genedata Biologics, used by top biopharma for biologics data management — directly overlapping Elucidata's Biologics Data Management offering.

Direct peers

  • Datavant: Datavant connects and de-identifies health data for research, comparable to Elucidata's multi-modal data harmonization and EHR integration work for biopharma customers.
  • Schrödinger: Schrödinger provides computational chemistry and biology software used by pharma for molecular design and target evaluation, overlapping directly with Elucidata's drug discovery software customer base.
  • Insitro: Insitro combines ML with biological data for target discovery and drug development, targeting similar biopharma customers and competing for the same platform-of-record position in AI-driven R&D.
  • Owkin: Owkin applies AI to biomedical and clinical data for drug discovery and target identification, selling into the same biopharma R&D buyer base as Elucidata and using multi-modal data and federated learning approaches.
  • DNAnexus: DNAnexus provides a cloud platform for biomedical data management and analysis, including multi-omics, similar to Elucidata's Polly Atlas and harmonization infrastructure for biopharma R&D.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Elucidata social profiles

Digital presence

Elucidata compliance and trust

Trust signal

Compliance4 records

Elucidata financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Elucidata leadership team

Management profile

Number of profiles

Profiles4 records

Elucidata funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Elucidata M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Elucidata

What does Elucidata do?

Elucidata delivers ML-ready, curated biomedical molecular data and operates Polly, a multi-modal agentic stack for target validation in drug discovery. Polly ingests proprietary and public biomedical data, connects evidence through knowledge graphs, scores target candidates across 14 dimensions, and delivers ranked decision-ready target lists. The platform is supplemented by managed services (Data Concierge, Metadata Curation, Data Quality Assessments, custom bioinformatics pipelines) and supports cloud, on-premise, or hybrid deployment for biopharma R&D teams.

Is Elucidata a public or private company?

Elucidata is a private company. It is classified as venture growth investor backed and is currently operating.

When was Elucidata founded?

Elucidata was founded in 2015. It employs 101 to 250 people.

Where is Elucidata based?

Elucidata is headquartered in San Francisco, United States, in the North America region.

How does Elucidata make money?

Three revenue lines are on record. Subscription Services (SaaS) is the primary driver. The others are professional Services and managed Services.

Who are Elucidata's main competitors?

Broad incumbents on record are Tempus, IQVIA, Benchling, Recursion Pharmaceuticals and Genedata. Direct peers are Datavant, Schrödinger, Insitro, Owkin and DNAnexus.

Does Elucidata have an API?

No public API is recorded for Elucidata.

What industry is Elucidata in?

Elucidata's product category is Drug Discovery & Biomedical Data Analytics Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAD, Bioinformatics & Multi-omics Analysis Software. Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireAxio BioPharma and Elucidata Partner to Connect R&D Data with Biomanufacturing WorkflowsAxio BioPharma and Elucidata announced a partnership to improve data continuity as biopharma programs move from research into process development and manufacturing. The collaboration combines Elucidata's Polly platform for data harmonization with Axio Lattice's federated network, aiming to preserve scientific context across organizational boundaries.Tracxn2026 Latest Shareholding & ValuationElucidata's latest cap table indicates a valuation of ₹458 Cr, with the Parent Entity holding 76.16%, Funds holding 23.83%, and the Founder holding 0.01%. IvyCap Ventures is listed as a specific shareholder within the capital structure. The data reflects the equity distribution across Seed, Seed 2, and Series A funding rounds.HpcwireData Science • AI • Advanced AnalyticsAbhishek Jha founded Elucidata in 2016 to address data fragmentation in biomedical R&D by building a platform that enhances data reliability and interoperability for pharmaceutical and biotech organizations. The company positions itself as a data-centric partner, leveraging AI to improve the quality of data used across research workflows.Business Wire IndiaElucidata Launches AI Labs to Solve Biomedical AGI across Human, Plant, and Animal HealthElucidata announced the launch of its AI Lab to develop advanced AI solutions for biomedical research and healthcare, focusing on out-of-distribution detection and analysis. The initiative aims to enhance AI's reliability in real-world biomedical applications by building models that can handle rare and unexpected data signals.BioTecNikaLife Sciences & Bioinformatics Job at Elucidata, Biomedical Data Curator Role!Elucidata is hiring a Biomedical Data Curator to work on AI-assisted curation and data harmonization for multi-omics datasets in Bengaluru or Delhi. The role requires expertise in Python, bioinformatics tools, and clinical data standards such as OMOP, FHIR, and HL7 to ensure high-quality biological data management.ElucidataEHR Data Integration: Challenges & Solutions for HealthcareThis article is an educational blog post explaining the key challenges in Electronic Health Record data integration—including data heterogeneity, interoperability issues, data quality problems, and regulatory compliance—and outlining best practices such as data standardization, automated pipelines, metadata management, and security governance. Elucidata uses the article to promote their Polly platform, positioning it as a solution that harmonizes fragmented EHR data into analysis-ready formats compatible with common data models like OMOP. The piece concludes with a forward-looking assertion that AI-driven systems will enable deeper insights from clinical data and transform healthcare data management.ElucidataKnowledge Graphs in Biomedicine: Unlocking Biomedical InsightsThe article details the application of knowledge graphs in biomedical research to integrate complex datasets for drug discovery, precision medicine, and clinical trial optimization. It highlights a case study where Elucidata assisted a therapeutics company in accelerating Acute Myeloid Leukemia target identification by reducing assessment time from 24 months to six months through AI-driven data harmonization.Warrington-worldwideThe science of selection: Werner Lanthaler’s data-driven approach to life science investmentWerner Lanthaler, former Evotec chief, applies a data-driven, long-term approach to biotech investment at Wlanholding, focusing on platform technologies and European innovators. He cites a 50%+ phase-one failure rate and 14-year drug development cycles, and recently joined Elucidata's board and led a $3M seed round in aTENSION.life.ElucidataStreamline Multi-Modal Data Management in Healthcare with AIThis blog article discusses the growing importance of multi-modal data integration in healthcare, highlighting challenges posed by data silos that fragment patient records, genomic data, and clinical imaging across incompatible systems. The piece outlines strategies including standardized data models (FHIR, HL7, OMOP), cloud infrastructure, and AI-driven automation to enable interoperability and improve patient outcomes. Elucidata's Polly platform is presented as a solution, with a use case citing a biopharma company that reduced data preparation time by 40% after adoption.ElucidataMetrics That Matter: How to Measure and Improve Data Quality in HealthcareData quality in healthcare is measured across accuracy, consistency, timeliness, relevance, and completeness, with metrics like error rate and completeness score. Elucidata's Polly platform automates validation and harmonization, and a diagnostics company using it reported 25% faster product development and $5 million in annual savings.